UVR-B-induced NKR-1 Expression in Ocular Tissues is blocked by Substance P Receptor Antagonist Fosaprepitant in the Exposed as well as Unexposed Partner Eye. (4th July 2021)

• Record Type: Journal Article
• Authors: Gross, Janine; Wegener, Alfred R.; Kronschläger, Martin; Schönfeld, Carl-Ludwig; Holz, Frank G.; Meyer, Linda M.
• Is Part Of: Ocular immunology and inflammation. Volume 29:Number 5(2021)
• Page Start: 963
• Page End: 975
• Publication Date: 2021-07-04
• Subjects: Ultraviolet radiation B -- Spantide I -- Fosaprepitant (IVEMEND®) -- neurokinin receptor 1 -- cytokines/chemokines; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2019.1708414
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To investigate the effect of NKR-1 antagonists in an established UVR-B-induced cataract mouse model. Furthermore, to examine the expression of pro-inflammatory cytokines/chemokines in mouse eyes following unilateral UVR-B exposure. Methods : Mice received intraperitoneally injections of Fosaprepitant and Spantide I, before and after unilateral exposure to UVR-B. After day 3 and 7 post-exposure, ocular tissues were extracted for the detection of NKR-1 protein level by ELISA. Results : Pretreatment with Fosaprepitant decreases NKR-1 expression in exposed ocular tissues as well as in the unexposed lens epithelium compared to the saline group. Spantide I treatment showed a tendency of NKR-1 overexpression in ocular tissues. Conclusion : The clinically approved NKR-1 receptor antagonist Fosaprepitant decreases NKR-1 protein expression effectively not only in the exposed but also in the unexposed partner eye in a UVR-B irradiation mouse model. No effect was seen on the protein concentration of pro-inflammatory cytokines/chemokines in either eye.